ALS News Today4h
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
marketinference23h
Denali Therapeutics Misses Primary Endpoint in ALS Trial
For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...